FDB (First Databank) vs Micromedex (2026)
The two drug knowledge incumbents, and almost nobody chooses between them the way this page implies, because most buyers already own both without knowing it: FDB sits inside the prescribing systems, Micromedex sits on the reference shelf. Where the comparison becomes real is when a health system asks which drug content it wants an AI product grounded in. Micromedex holds the stronger position on that question, because it is recognised as a drug compendium under United States federal law, which gives its content a standing in coverage decisions that no competitor's has, and it has a peer reviewed usability evaluation behind it. FDB holds the deeper distribution by far and the cleaner licensing architecture. Neither publishes a security attestation, a price, or any description of the model layer now being added on top of decades of curated content.
- Distribution nothing else in this index approaches. The drug databases are embedded inside the systems used by the majority of American hospitals, physician practices and pharmacies, so most interaction and dose warnings clinicians already see are built on this content.
- The historical arrangement is clean by design: content is licensed into customers' own systems, which places hosting, residency and processing questions with those customers rather than with the supplier.
- Its own newer products are framed conservatively, with a prescription agent producing orders explicitly for physician review and the verification product named as an assistant rather than a decision maker.
- It holds a regulatory status nothing else in this category has: recognition as a drug compendium under United States federal law, which means coverage and reimbursement decisions can reference it directly.
- The evidence position is stronger than most of this category, including a peer reviewed usability evaluation of the combined drug and disease product published in 2023 with authors from a major academic hospital.
- Every result carries a citation that opens the underlying source in one click, over a corpus curated from primary literature with in line referencing and daily updates, and integration is corroborated by structured third party customer feedback rather than only claimed.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. FDB (First Databank) and Micromedex are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | FDB (First Databank) | Micromedex |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Clinical Reference & Evidence |
| Headquarters | South San Francisco, California, United States | Ann Arbor, Michigan |
| Website | fdbhealth.com | merative.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards FDB (First Databank) its top capability grade on EHR and Interoperability Depth. Set against Micromedex, FDB (First Databank) grades higher on EHR and Interoperability Depth. Its thinnest published disclosure sits on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Micromedex on any axis it scores. Set against FDB (First Databank), Micromedex grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose FDB (First Databank) or Micromedex?
On the axes where the AI Health Index separates them, FDB (First Databank) grades higher on EHR and Interoperability Depth, and Micromedex grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and Clinical and Operational Evidence. Micromedex leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do FDB (First Databank) and Micromedex differ most?
The widest separation the AI Health Index records between FDB (First Databank) and Micromedex is on EHR and Interoperability Depth, where FDB (First Databank) grades A and Micromedex grades B. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do FDB (First Databank) and Micromedex grade the same?
The AI Health Index grades FDB (First Databank) and Micromedex the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have FDB (First Databank) and Micromedex not disclosed?
At the last review, at least one of FDB (First Databank) and Micromedex published thin or absent detail on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither vendor publishes a security attestation, trust centre, penetration testing statement or vulnerability disclosure programme, and neither publishes pricing, a pricing unit or a contract shape. FDB publishes no health privacy statement or business associate terms at all, which matters more now that its newer protocol server is described as serving drug knowledge in patient specific contexts rather than as static licensed content.
The exposure specific to FDB is concentration rather than discrimination: when one curated knowledge base sits underneath most medication decisions in a country, a gap or an error propagates everywhere at once, and no bias assessment, coverage analysis or governance documentation was located. Neither vendor describes its generative layer, its models or its evaluation method.